MA38399B2 - Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique - Google Patents

Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique

Info

Publication number
MA38399B2
MA38399B2 MA38399A MA38399A MA38399B2 MA 38399 B2 MA38399 B2 MA 38399B2 MA 38399 A MA38399 A MA 38399A MA 38399 A MA38399 A MA 38399A MA 38399 B2 MA38399 B2 MA 38399B2
Authority
MA
Morocco
Prior art keywords
heart failure
formulation
useful
tablet form
treating acute
Prior art date
Application number
MA38399A
Other languages
English (en)
Other versions
MA38399A1 (fr
Inventor
Mingda Bi
Robert Kuehl
Original Assignee
Amgen Inc
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38399(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc, Cytokinetics Inc filed Critical Amgen Inc
Publication of MA38399A1 publication Critical patent/MA38399A1/fr
Publication of MA38399B2 publication Critical patent/MA38399B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne certaines formulations pharmaceutiques d'omécamtiv mécarbil et leurs procédés de préparation et d'utilisation.
MA38399A 2013-03-14 2014-03-14 Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique MA38399B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785763P 2013-03-14 2013-03-14
PCT/US2014/027104 WO2014152236A1 (fr) 2013-03-14 2014-03-14 Composés hétérocycliques et leurs utilisations

Publications (2)

Publication Number Publication Date
MA38399A1 MA38399A1 (fr) 2017-01-31
MA38399B2 true MA38399B2 (fr) 2020-12-31

Family

ID=50549466

Family Applications (2)

Application Number Title Priority Date Filing Date
MA38399A MA38399B2 (fr) 2013-03-14 2014-03-14 Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
MA44637A MA44637B1 (fr) 2013-03-14 2014-03-14 Composes hétérocycliques et leurs utilisations

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA44637A MA44637B1 (fr) 2013-03-14 2014-03-14 Composes hétérocycliques et leurs utilisations

Country Status (41)

Country Link
US (13) US9951015B2 (fr)
EP (3) EP2970123B1 (fr)
JP (5) JP6498658B2 (fr)
KR (2) KR102374159B1 (fr)
CN (3) CN105120844A (fr)
AP (1) AP2015008789A0 (fr)
AR (1) AR095542A1 (fr)
AU (2) AU2014239995B2 (fr)
BR (2) BR112015022857B1 (fr)
CA (3) CA2902436A1 (fr)
CL (1) CL2015002708A1 (fr)
CR (1) CR20150549A (fr)
CY (2) CY1122695T1 (fr)
DK (2) DK2970123T3 (fr)
EA (1) EA031185B1 (fr)
ES (2) ES2837038T3 (fr)
HK (4) HK1218080A1 (fr)
HR (2) HRP20191728T1 (fr)
HU (2) HUE052355T2 (fr)
IL (2) IL240788B (fr)
JO (1) JOP20140114B1 (fr)
LT (2) LT2968173T (fr)
MA (2) MA38399B2 (fr)
ME (1) ME03566B (fr)
MX (3) MX363347B (fr)
MY (1) MY186048A (fr)
NZ (1) NZ711225A (fr)
PE (1) PE20151786A1 (fr)
PH (2) PH12015501998B1 (fr)
PL (2) PL2970123T3 (fr)
PT (2) PT2970123T (fr)
RS (2) RS61215B1 (fr)
RU (1) RU2663663C2 (fr)
SA (1) SA515361088B1 (fr)
SG (2) SG11201507258PA (fr)
SI (2) SI2968173T1 (fr)
TN (1) TN2015000380A1 (fr)
TW (1) TWI667026B (fr)
UA (1) UA117011C2 (fr)
UY (1) UY35449A (fr)
WO (2) WO2014152270A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2968173T1 (sl) * 2013-03-14 2021-04-30 Amgen Inc. Heterociklične spojine in njihove uporabe
TWI790189B (zh) 2015-01-02 2023-01-21 美商梅拉洛伊卡公司 細菌組成物
JP6858716B2 (ja) 2015-06-26 2021-04-14 アムジエン・インコーポレーテツド 心筋ミオシン活性化剤と洞房結節Ｉｆ電流阻害剤の併用療法
US11576910B2 (en) 2017-06-30 2023-02-14 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
US11040956B2 (en) 2017-06-30 2021-06-22 Amgen Inc. Synthesis of omecamtiv mecarbil
EA039850B1 (ru) * 2018-04-30 2022-03-21 Эмджен Инк. Синтез омекамтива мекарбила
SI3594199T1 (sl) * 2018-07-09 2020-10-30 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Kristalinični 2-fluoro-3-nitrotoluen in postopek za njegovo pripravo
WO2020014406A1 (fr) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Formes à l'état solide d'omecamtiv mecarbil et d'omecamtiv mecarbil dihcl
WO2020037164A1 (fr) * 2018-08-17 2020-02-20 Amgen Inc. Sel et formes cristallines d'omecamtiv mecarbil
CA3133243A1 (fr) * 2019-03-12 2020-09-17 Amgen Inc. Polymorphes et co-cristaux d'un activateur de troponine cardiaque
EP3938042A1 (fr) * 2019-03-12 2022-01-19 Amgen Inc. Polymorphes d'un activateur de troponine cardiaque
WO2021053175A1 (fr) 2019-09-19 2021-03-25 Synthon B.V. Sels d'omecamtiv mecarbil et formes solides de ceux-ci
US20220340542A1 (en) 2019-09-19 2022-10-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4041198A4 (fr) * 2019-10-09 2023-08-16 Dr. Reddy's Laboratories Limited Formes solides de dichlorhydrate d'omecamtiv mecarbil et procédés associés
AU2021221106A1 (en) * 2020-02-10 2022-09-22 Amgen Inc. Omecamtiv mecarbil tablet
KR20230107282A (ko) 2020-11-12 2023-07-14 암젠 인크 오메캄티브 메카빌을 투여하여 심부전을 치료하는 방법
WO2022177927A1 (fr) * 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Forme cristalline non hydratée de sel de dihydrobromure d'omecamtiv mecarbil
IL305751A (en) 2021-03-10 2023-11-01 Amgen Inc SYNTHESIS OF OMECAMTIV MECARBIL
WO2024081611A1 (fr) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Méthodes de traitement de l'insuffisance cardiaque par administration d'activateurs de sarcomère cardiaque
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2788775B1 (fr) 1999-01-22 2001-04-13 Pf Medicament Nouvelles n-alcoyl-n-[1-(omega-(arylalcoyloxy)alcoyl] piperidin-4-yl]-4h-3,1-benzo(thia/oxa)zines-2-amines substituees, leur preparation et leur application en therapeutique
CA2395333C (fr) 1999-12-23 2009-01-13 Pfizer Products Inc. Forme de dosage de medicament entraine par un hydrogel
GB0124455D0 (en) 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
WO2003032965A2 (fr) 2001-10-17 2003-04-24 King Pharmaceuticals Research And Development, Inc Methode de reduction du diabete de type 2 chez des patients a haut risque
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
ES2686357T3 (es) * 2004-06-17 2018-10-17 Cytokinetics, Inc. Compuestos, composiciones y procedimientos
WO2007054975A1 (fr) 2005-11-08 2007-05-18 Panacea Biotec Ltd Compositions pharmaceutiques destinees au traitement de troubles cardiovasculaires et d'autres troubles associes
PE20100742A1 (es) 2005-11-15 2010-11-25 Glaxo Group Ltd Nuevos procedimientos y formulaciones
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
US20070161617A1 (en) 2005-12-15 2007-07-12 Morgan Bradley P Certain chemical entities, compositions and methods
JP5178526B2 (ja) * 2005-12-19 2013-04-10 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
US7639112B2 (en) 2007-04-25 2009-12-29 Sony Corporation Fuse device with integrated switch
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
TW201006816A (en) * 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
CA2739463C (fr) 2008-10-03 2018-07-03 Pericor Therapeutics, Inc. Procedes et compositions pour le traitement de l'insuffisance cardiaque aigue
US9253433B2 (en) 2012-11-27 2016-02-02 International Business Machines Corporation Method and apparatus for tagging media with identity of creator or scene
SI2968173T1 (sl) * 2013-03-14 2021-04-30 Amgen Inc. Heterociklične spojine in njihove uporabe
JP6634368B2 (ja) * 2013-03-14 2020-01-22 アムジエン・インコーポレーテツド 複素環式化合物及びそれらの使用
CA2975260C (fr) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues de 2-(tert-butylamino)-4-((1r,3r,4r) -3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
JP6858716B2 (ja) 2015-06-26 2021-04-14 アムジエン・インコーポレーテツド 心筋ミオシン活性化剤と洞房結節Ｉｆ電流阻害剤の併用療法
US11576910B2 (en) 2017-06-30 2023-02-14 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
US11040956B2 (en) 2017-06-30 2021-06-22 Amgen Inc. Synthesis of omecamtiv mecarbil
SI3594199T1 (sl) 2018-07-09 2020-10-30 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Kristalinični 2-fluoro-3-nitrotoluen in postopek za njegovo pripravo
WO2020014406A1 (fr) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Formes à l'état solide d'omecamtiv mecarbil et d'omecamtiv mecarbil dihcl
WO2020037164A1 (fr) 2018-08-17 2020-02-20 Amgen Inc. Sel et formes cristallines d'omecamtiv mecarbil
WO2020131574A1 (fr) 2018-12-18 2020-06-25 Amgen Inc. Procédé de réduction de composés nitro aromatiques
WO2021053175A1 (fr) 2019-09-19 2021-03-25 Synthon B.V. Sels d'omecamtiv mecarbil et formes solides de ceux-ci
US20220340542A1 (en) 2019-09-19 2022-10-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4041198A4 (fr) 2019-10-09 2023-08-16 Dr. Reddy's Laboratories Limited Formes solides de dichlorhydrate d'omecamtiv mecarbil et procédés associés
WO2021070124A1 (fr) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Nouveaux procédés destinés à la préparation de l'omécamtiv mécarbil
WO2021136477A1 (fr) 2020-01-03 2021-07-08 苏州科睿思制药有限公司 Co-cristal de dichlorhydrate du composé i et son procédé de préparation et son utilisation
AU2021221106A1 (en) 2020-02-10 2022-09-22 Amgen Inc. Omecamtiv mecarbil tablet
KR20230107282A (ko) 2020-11-12 2023-07-14 암젠 인크 오메캄티브 메카빌을 투여하여 심부전을 치료하는 방법
WO2022177927A1 (fr) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Forme cristalline non hydratée de sel de dihydrobromure d'omecamtiv mecarbil
IL305751A (en) 2021-03-10 2023-11-01 Amgen Inc SYNTHESIS OF OMECAMTIV MECARBIL

Also Published As

Publication number Publication date
US20200331859A1 (en) 2020-10-22
SI2970123T1 (sl) 2019-12-31
WO2014152236A1 (fr) 2014-09-25
UY35449A (es) 2014-09-30
CA2902436A1 (fr) 2014-09-25
MA38399A1 (fr) 2017-01-31
AU2014240049B2 (en) 2018-07-19
US20180312469A1 (en) 2018-11-01
US20240217933A1 (en) 2024-07-04
HK1218544A1 (zh) 2017-02-24
PH12019500176A1 (en) 2020-11-04
SG11201507258PA (en) 2015-10-29
SA515361088B1 (ar) 2018-07-22
NZ711225A (en) 2020-06-26
PH12015501998A1 (en) 2016-01-11
BR112015023417A2 (pt) 2017-07-18
CL2015002708A1 (es) 2016-03-11
JP2022023891A (ja) 2022-02-08
TW201524507A (zh) 2015-07-01
RS61215B1 (sr) 2021-01-29
JP6966590B2 (ja) 2021-11-17
PL2970123T3 (pl) 2020-03-31
EA031185B1 (ru) 2018-11-30
HK1218080A1 (zh) 2017-02-03
CA2902646A1 (fr) 2014-09-25
CA3147180C (fr) 2024-04-23
MA44637B1 (fr) 2021-04-30
MX363347B (es) 2019-03-20
AU2014239995A1 (en) 2015-09-10
IL240788B (en) 2020-09-30
CN105120844A (zh) 2015-12-02
RU2015143643A (ru) 2017-04-18
US20140309235A1 (en) 2014-10-16
UA117011C2 (uk) 2018-06-11
AU2014240049A1 (en) 2015-09-10
SI2968173T1 (sl) 2021-04-30
WO2014152270A1 (fr) 2014-09-25
US9988354B2 (en) 2018-06-05
MX2021001231A (es) 2021-04-12
AU2014240049C1 (en) 2019-03-07
TWI667026B (zh) 2019-08-01
US11884630B2 (en) 2024-01-30
EP3821882A1 (fr) 2021-05-19
DK2970123T3 (da) 2019-10-21
CR20150549A (es) 2016-01-04
JOP20140114B1 (ar) 2021-08-17
CN108785265A (zh) 2018-11-13
AP2015008789A0 (en) 2015-10-31
ES2750676T3 (es) 2020-03-26
US11384053B2 (en) 2022-07-12
HUE052355T2 (hu) 2021-04-28
CN105209437B (zh) 2018-09-18
EP2968173A1 (fr) 2016-01-20
BR112015022857B1 (pt) 2022-10-25
PT2968173T (pt) 2020-12-18
NZ750950A (en) 2020-09-25
CA3147180A1 (fr) 2014-09-25
CN105209437A (zh) 2015-12-30
US20220153700A1 (en) 2022-05-19
US20160016906A1 (en) 2016-01-21
LT2970123T (lt) 2019-11-11
US20230044617A1 (en) 2023-02-09
PH12015501998B1 (en) 2016-01-11
CY1123633T1 (el) 2022-03-24
HUE046285T2 (hu) 2020-02-28
JP7174132B2 (ja) 2022-11-17
KR20150136063A (ko) 2015-12-04
ES2837038T3 (es) 2021-06-29
KR102374159B1 (ko) 2022-03-15
JP2016513683A (ja) 2016-05-16
MX2015012414A (es) 2016-04-25
JP2019059746A (ja) 2019-04-18
KR102474467B1 (ko) 2022-12-05
JP2020125307A (ja) 2020-08-20
EA201591728A1 (ru) 2016-01-29
US20220298114A1 (en) 2022-09-22
EP2970123A1 (fr) 2016-01-20
ME03566B (fr) 2020-07-20
MA44637A1 (fr) 2019-08-30
EP2968173B1 (fr) 2020-10-14
KR20220045014A (ko) 2022-04-12
PE20151786A1 (es) 2015-12-11
US20240101517A1 (en) 2024-03-28
RS59536B1 (sr) 2019-12-31
US20200399221A1 (en) 2020-12-24
US11472773B2 (en) 2022-10-18
CA2902646C (fr) 2022-08-16
JP6498658B2 (ja) 2019-04-10
JP6783138B2 (ja) 2020-11-11
US11958809B2 (en) 2024-04-16
US9951015B2 (en) 2018-04-24
US10421726B2 (en) 2019-09-24
SG10201706656RA (en) 2017-09-28
IL241089B (en) 2019-10-31
MY186048A (en) 2021-06-17
TN2015000380A1 (en) 2017-01-03
US20200079736A1 (en) 2020-03-12
JP2016519071A (ja) 2016-06-30
BR112015022857A2 (pt) 2017-07-18
EP2970123B1 (fr) 2019-08-14
US20180273479A1 (en) 2018-09-27
HK1218512A1 (zh) 2017-02-24
LT2968173T (lt) 2021-03-25
IL240788A0 (en) 2015-10-29
CY1122695T1 (el) 2021-03-12
US20200277261A1 (en) 2020-09-03
HRP20201967T1 (hr) 2021-03-05
HRP20191728T1 (hr) 2019-12-13
HK1219484A1 (zh) 2017-04-07
PT2970123T (pt) 2019-10-28
IL241089A0 (en) 2015-11-30
AU2014239995B2 (en) 2018-07-26
RU2663663C2 (ru) 2018-08-08
JP6689942B2 (ja) 2020-04-28
DK2968173T3 (da) 2020-12-21
AR095542A1 (es) 2015-10-21
MX2015012429A (es) 2016-04-07
BR112015023417B1 (pt) 2023-10-17
PL2968173T3 (pl) 2021-03-08

Similar Documents

Publication Publication Date Title
MA38399A1 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
UA109650C2 (xx) Біс-арилзв'язані арилтриазолони та їх застосування
PH12014501991B1 (en) Phenicol antibacterials
EA201692007A1 (ru) Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
MX2013003635A (es) Compuestos de n-heteroarilo.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
WO2016030899A8 (fr) Méthodes de traitement de la sclérose latérale amyotrophique
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif
UA109944U (uk) Фармацевтична композиція для зниження рівня n-оксиду триметиламіну
TR201815617A2 (tr) Deksketoprofen içeren bir formülasyon.
EA033077B1 (ru) Фармацевтическая композиция, содержащая 13 глицеридов, и ее препараты и их применение
EA201491477A1 (ru) Фармацевтические составы, содержащие флупиртин
MA38426B1 (fr) Compositions antibiotiques de ceftolozane
UA88138U (ru) Лекарственное средство в форме перорального раствора для лечения и профилактики ишемии тканей организма
UA107884C2 (en) Combined anti-tuberculosis drug
UA99891C2 (ru) Производные метил-3-(3-r-6-r-имидазо[1,2-а]пиридин-2-ил)акрилата и способ их получения